Novo Nordisk wins Dutch court order against Ceban over semaglutide

Investing.com -- Novo Nordisk announced on Wednesday that a district court in the Netherlands granted the company a preliminary injunction against Ceban Ziekenhuisfarmacie in a patent infringement case related to a compounded semaglutide nasal spray.

Semaglutide serves as the active ingredient in Novo Nordisk's weight-loss drug Wegovy.

The Danish drugmaker said the court determined that Ceban violated Novo Nordisk's supplementary protection certificate covering semaglutide.

The court ordered the Dutch company to stop the infringing activities, remove product listings, disclose supply chain information, and reimburse Novo Nordisk's legal costs.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• Epic Gold plans $3.15M non-brokered private placement
• Honeywell Aerospace (HONA) dropped from S&P 100